5-MAPDI (also known as Indanylmethylaminopropane or IMP) is an entactogenic amphetamine derivative which is structurally related to MDMA as well as to dihydrobenzofuran derivatives such as 5-MAPDB and 6-MAPDB, and has been sold as a designer drug. It has reportedly been sold over grey-market websites since around 2014, although the first definitive identification was not made until September 2016 by a forensic laboratory in Slovenia.[1]

See also

References

  1. ^ European Monitoring Center for Drugs and Drug Addiction – Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA
Allikas: http://en.wikipedia.org/wiki/5-MAPDI
No tags for this post.